ATE306916T1 - Neue fettanaloge zur behandlung von sekundärer restenose - Google Patents

Neue fettanaloge zur behandlung von sekundärer restenose

Info

Publication number
ATE306916T1
ATE306916T1 AT99940723T AT99940723T ATE306916T1 AT E306916 T1 ATE306916 T1 AT E306916T1 AT 99940723 T AT99940723 T AT 99940723T AT 99940723 T AT99940723 T AT 99940723T AT E306916 T1 ATE306916 T1 AT E306916T1
Authority
AT
Austria
Prior art keywords
sub
treatment
new fat
analogues
restenosis
Prior art date
Application number
AT99940723T
Other languages
English (en)
Inventor
Rolf Berge
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Application granted granted Critical
Publication of ATE306916T1 publication Critical patent/ATE306916T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT99940723T 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose ATE306916T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
PCT/NO1999/000149 WO1999058123A2 (en) 1998-05-08 1999-05-07 Novel fatty acid analogues for the treatment of primary and secondary restenosis

Publications (1)

Publication Number Publication Date
ATE306916T1 true ATE306916T1 (de) 2005-11-15

Family

ID=19907879

Family Applications (5)

Application Number Title Priority Date Filing Date
AT99933293T ATE245416T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes
AT02024388T ATE334666T1 (de) 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung der fettleber
AT02024616T ATE336239T1 (de) 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung des bluthochdrucks
AT99933292T ATE247464T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit
AT99940723T ATE306916T1 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Family Applications Before (4)

Application Number Title Priority Date Filing Date
AT99933293T ATE245416T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes
AT02024388T ATE334666T1 (de) 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung der fettleber
AT02024616T ATE336239T1 (de) 1998-05-08 1999-04-23 Neue fettsäureanaloge zur behandlung des bluthochdrucks
AT99933292T ATE247464T1 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit

Country Status (18)

Country Link
US (4) US6365628B1 (de)
EP (5) EP1075258B1 (de)
JP (3) JP2002514595A (de)
KR (3) KR100701503B1 (de)
CN (3) CN1223343C (de)
AT (5) ATE245416T1 (de)
AU (4) AU7240398A (de)
BR (2) BR9910297A (de)
CA (3) CA2331408C (de)
DE (5) DE69932864D1 (de)
DK (3) DK1075258T3 (de)
ES (3) ES2207253T3 (de)
HK (3) HK1034912A1 (de)
NO (3) NO20005463L (de)
NZ (3) NZ508047A (de)
PT (2) PT1075259E (de)
RU (3) RU2221558C2 (de)
WO (4) WO1999058120A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
AU784123B2 (en) * 1999-10-13 2006-02-09 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
NO328803B1 (no) 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20006008L (no) 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
DK1547614T3 (da) * 2002-05-28 2011-04-04 Ajinomoto Kk Medicinsk sammensætning til inhibering af ekspressionen af ATP-citrat-lyase og anvendelse deraf
JP5008258B2 (ja) 2002-06-20 2012-08-22 アイシー・ベック・リミテッド 含硫黄ホスホリピド誘導体
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
RU2005106274A (ru) 2002-09-06 2005-11-10 Янссен Фармацевтика, Н.В. (Be) Гетероциклические соединения
US20040092590A1 (en) * 2002-09-27 2004-05-13 Linda Arterburn Glycemic control for prediabetes and/or diabetes Type II using docosahexaenoic acid
CA2501318A1 (en) * 2002-10-10 2004-04-22 Yeda Research And Development Co. Ltd Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
JP2006519229A (ja) 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ 視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節
EP1718602A4 (de) * 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd Therapeutische und trägermoleküle
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
CA2566723A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. New intravenous drug administration and blood sampling model in the awake rat
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
KR20070054637A (ko) * 2004-07-19 2007-05-29 티아 메디카 에이에스 식물유 및/또는 어유 및 비-산화성 지방산 구성요소를포함하는 조성물
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006083439A2 (en) * 2004-12-28 2006-08-10 The Research Foundation Of State University Of New York At Buffalo Method for lowering serum homocysteine
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
EP1888727B1 (de) 2005-05-04 2015-04-15 Pronova BioPharma Norge AS Neue dha-derivate und ihre verwendung als medikamente
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
CA2666846C (en) 2006-10-20 2018-04-10 Cpd, Llc Method of restoring the incretin effect
CN101535238A (zh) * 2006-11-01 2009-09-16 普罗诺瓦生物医药挪威公司 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质
EP2129646A2 (de) * 2006-11-01 2009-12-09 Pronova Biopharma Norge AS Omega-3-lipidverbindungen
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
US20080221115A1 (en) * 2007-02-26 2008-09-11 Liat Hayardeny-Nisimov Use of long-chain alcohol derivatives for the treatment of alopecia areata
EP2214481B1 (de) 2007-10-15 2019-05-01 United Animal Health, Inc. Verfahren zur erhöhung der leistung von nachkommen
EP2217558A1 (de) * 2007-10-31 2010-08-18 Pronova Biopharma Norge AS Neue dha-derivate und ihre verwendung als medikamente
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
JP5373888B2 (ja) * 2008-04-29 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー Ｃｐｔ２インヒビターとしての４−トリメチルアンモニオ−ブチラート類
EP2147910A1 (de) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Neue Lipid-Verbindungen
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
JP5843755B2 (ja) 2009-05-08 2016-01-13 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 心血管性、代謝性および炎症性疾患領域に関する疾患の処置のための多価不飽和脂肪酸
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
EP2724739B1 (de) 2009-07-30 2015-07-01 Tandem Diabetes Care, Inc. Tragbares Infusionspumpensystem
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
US20130209550A1 (en) 2010-07-28 2013-08-15 Life Technologies Corporation Anti-Viral Azide Containing Compounds
SG190114A1 (en) 2010-11-05 2013-07-31 Pronova Biopharma Norge As Methods of treatment using lipid compounds
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MX2015011074A (es) 2013-02-28 2016-03-09 Pronova Biopharma Norge As Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma.
EP2968568A2 (de) 2013-03-11 2016-01-20 Life Science Nutrition AS Natürliche lipide mit nicht oxidierbaren fettsäuren
US10154979B2 (en) 2013-03-11 2018-12-18 Sciadonics, Inc. Lipid compositions containing bioactive fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
ES2787223T3 (es) 2014-11-07 2020-10-15 Univ Minnesota Sales y composiciones útiles para tratar enfermedades
JP6784696B2 (ja) 2015-04-28 2020-11-11 プロノヴァ バイオファーマ ノルゲ エーエス 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び／又は治療のための使用
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
US10792266B2 (en) 2017-10-23 2020-10-06 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
KR20200096791A (ko) 2017-12-06 2020-08-13 바스프 에이에스 비알콜성 지방간염 치료용 지방산 유도체
EP3934639A4 (de) * 2019-03-04 2023-01-11 Epitracker, Inc. Fettsäureanaloge und deren verwendung zur behandlung von kognitiven beeinträchtigungen, verhaltenszuständen und chronischen schmerzen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
WO1996040098A2 (en) * 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
DE69622722T2 (de) * 1996-11-20 2003-02-27 Nutricia Nv Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS

Also Published As

Publication number Publication date
NO20005462L (no) 2001-01-08
WO1999058121A1 (en) 1999-11-18
EP1075259A1 (de) 2001-02-14
EP1075258A1 (de) 2001-02-14
KR20010043316A (ko) 2001-05-25
DK1075260T3 (da) 2006-02-06
CN1300212A (zh) 2001-06-20
NO20005463L (no) 2001-01-08
US6365628B1 (en) 2002-04-02
DE69909775D1 (de) 2003-08-28
KR20010043315A (ko) 2001-05-25
ATE247464T1 (de) 2003-09-15
AU761355B2 (en) 2003-06-05
RU2219920C2 (ru) 2003-12-27
CN1245157C (zh) 2006-03-15
CA2331393C (en) 2009-08-11
DE69909775T2 (de) 2004-06-03
NZ508046A (en) 2003-08-29
DE69927805T2 (de) 2006-07-06
NZ508047A (en) 2003-05-30
ATE245416T1 (de) 2003-08-15
JP2002514596A (ja) 2002-05-21
AU4936799A (en) 1999-11-29
US7026356B2 (en) 2006-04-11
HK1034911A1 (en) 2001-11-09
NO20005463D0 (no) 2000-10-30
ES2251218T3 (es) 2006-04-16
AU7240398A (en) 1999-11-29
JP5057003B2 (ja) 2012-10-24
EP1285652B1 (de) 2006-08-16
WO1999058122A1 (en) 1999-11-18
RU2221558C2 (ru) 2004-01-20
US20020198259A1 (en) 2002-12-26
PT1075259E (pt) 2003-12-31
US6441036B1 (en) 2002-08-27
DE69932645D1 (de) 2006-09-14
NO333143B1 (no) 2013-03-18
DK1075258T3 (da) 2003-12-01
AU4936699A (en) 1999-11-29
NO20005461D0 (no) 2000-10-30
JP4465672B2 (ja) 2010-05-19
CA2331395C (en) 2008-10-14
CN1302204A (zh) 2001-07-04
EP1285652A1 (de) 2003-02-26
CA2331395A1 (en) 1999-11-18
EP1075260A2 (de) 2001-02-14
ES2204142T3 (es) 2004-04-16
JP2002514595A (ja) 2002-05-21
ATE336239T1 (de) 2006-09-15
CA2331393A1 (en) 1999-11-18
KR100822077B1 (ko) 2008-04-14
EP1075260B1 (de) 2005-10-19
DE69932864D1 (de) 2006-09-28
BR9910297A (pt) 2002-01-02
DE69910559T2 (de) 2004-06-17
CN1223343C (zh) 2005-10-19
EP1284139A1 (de) 2003-02-19
CN1244323C (zh) 2006-03-08
HK1034912A1 (en) 2001-11-09
NO20005461L (no) 2001-01-08
DE69927805D1 (de) 2006-03-02
AU5451799A (en) 1999-11-29
CA2331408C (en) 2008-10-21
WO1999058123A2 (en) 1999-11-18
BR9910296A (pt) 2002-01-15
US6417232B1 (en) 2002-07-09
JP2002514594A (ja) 2002-05-21
EP1075258B1 (de) 2003-08-20
AU762790B2 (en) 2003-07-03
HK1034909A1 (en) 2001-11-09
WO1999058123A3 (en) 2000-03-09
RU2223095C2 (ru) 2004-02-10
DE69910559D1 (de) 2003-09-25
CA2331408A1 (en) 1999-11-18
WO1999058120A1 (en) 1999-11-18
AU762792B2 (en) 2003-07-03
DK1075259T3 (da) 2003-11-03
PT1075258E (pt) 2004-01-30
KR100701503B1 (ko) 2007-04-02
EP1075259B1 (de) 2003-07-23
CN1300211A (zh) 2001-06-20
NZ508045A (en) 2003-08-29
KR20010043314A (ko) 2001-05-25
NO20005462D0 (no) 2000-10-30
ATE334666T1 (de) 2006-08-15
ES2207253T3 (es) 2004-05-16
KR100701502B1 (ko) 2007-04-02
EP1284139B1 (de) 2006-08-02

Similar Documents

Publication Publication Date Title
ATE306916T1 (de) Neue fettanaloge zur behandlung von sekundärer restenose
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
TR200200706T2 (tr) Nöropatik ağrı tedavisi için retigabin kullanımı.
NZ335981A (en) Ketobenzamides as calpain inhibitors
ATE263157T1 (de) Nematizide trifluorbutene
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
ATE283256T1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
DK1204659T3 (da) Serotonerge benzofuraner
TR199903159T2 (xx) Yeni �-Amino ve �-Azido karbonik asit t�revleri.
PT1651596E (pt) Novos derivados de 4,4?-ditiobis-(3-aminobutano-1-sulfonatos) e composições que os contêm
DE60204014D1 (de) Chlormethylierung von thiophene
DE60043228D1 (de) Herstellungsverfahren von 2-cyanopyridinen
UA26982A1 (uk) Похідhі малоhової кислоти, які проявляють властивості іhгібітору росту рослиh

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1075260

Country of ref document: EP

REN Ceased due to non-payment of the annual fee